Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Daito Pharmaceutical Co., Ltd. ( (JP:4577) ).
Daito Pharmaceutical Co., Ltd. announced significant changes in its board and executive leadership, including the selection of Minori Uchida as a new Board Director and Audit and Supervisory Committee Member. Uchida brings extensive international finance experience, which is expected to enhance the company’s management strategies and corporate governance. Additionally, the company is reshuffling its executive team to strengthen its operational divisions, potentially impacting its market positioning and stakeholder relations.
More about Daito Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development and sale of drug products. The company is listed on the Prime Market of the Tokyo Stock Exchange and is led by President and CEO Hiroshi Matsumori.
Average Trading Volume: 78,388
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen30.87B
For detailed information about 4577 stock, go to TipRanks’ Stock Analysis page.